Dyne Therapeutics completes enrollment in ACHIEVE trial expansion cohort for z-basivarsen in DM1

Dyne Therapeutics Inc

DYN

0.00

Dyne Therapeutics completed enrollment in a 71-participant registrational expansion cohort of its Phase 1/2 ACHIEVE trial for z-basivarsen in DM1.
Results have not been presented; topline data are scheduled for Q1 2027.
The readout is intended to support a potential U.S. Accelerated Approval filing in Q3 2027, using data across the ACHIEVE program.
Management expects the dataset to show improvement in myotonia, with supportive trends on functional outcomes.
A potential U.S. launch is targeted for H1 2028, subject to Priority Review timing and FDA approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606030730PRIMZONEFULLFEED9730843) on June 03, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.